Pinelopi Voulgari

Pinelopi Voulgari

Auto-generated profile, based on publicly available information

Pinelopi Voulgari

University Hospital of Ioannina, Rheumatology Clinic, Ioannina, Greece

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
ACAnthoula Chatzikyriakidou
Anthoula Chatzikyriakidou
Ioannis GeorgiouIoannis Georgiou
Ioannis Georgiou
PVP. V. Voulgari
P. V. Voulgari
AGA. N. Georgiadis
A. N. Georgiadis
EAEvangelia Argyriou
Evangelia Argyriou
ADA. A. Drosos
A. A. Drosos
Deregulation of glucocorticoid (GC) secretion could be associated with rheumatoid arthritis (RA). The GC receptor (GR) has two isoforms. In the present study, we explored the role of GR-alpha polymorphisms rs33388, rs33389, and Bcl I, and the GR-beta variant rs6198 in RA susceptibility. One hundred and thirty-six RA patients and 148 ethnic matching controls were studied. Polymorphisms rs33388 and Bcl I were genotyped by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP), and variants rs33389 and rs6198 by polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) coupled with sequencing. Arlequin and SPSS softwares were used in the statistical analysis. The polymorphisms studied were in Hardy-Weinberg equilibrium in both groups. A marginally statistical significant difference was observed in the distribution of rs33388 genotypes between RA patients and controls (p = 0.053). When the A and T alleles were compared, the statistical significance was p = 0.025. Specific complex genotypes were also differentially distributed: the GR-alpha complex genotypes (a) [homozygote (homo) wild-type (wt) rs33388-homo wt rs33389] (11% RA vs. 21% controls; p = 0.023), (b) [homo wt rs33388-homo wt rs33389-homo non-wt Bcl I] (0.7% RA vs. 4.7% controls; p = 0.042), and (c) the GR-beta complex genotype [homo wt rs33388-homo wt rs33389-homo non-wt Bcl I-homo wt rs6198] (0.7% RA vs. 4.7% controls; p = 0.042). GR-alpha and GR-beta polymorphisms are potentially associated with RA susceptibility. However, additional studies in larger and other ethnic groups of patients are needed to confirm the results of the present study.

1 November 2005 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SNS N Nikas
S N Nikas
PVP V Voulgari
P V Voulgari
ITI P Takalou
I P Takalou
PKPelagia Katsimbri
Pelagia Katsimbri
ADA. A. Drosos
A. A. Drosos
Five patients (three male, two female; mean (SD) age 41.0 (3.3) years) with longstanding disease (7.9 (3.7) years) refractory to immunosuppressive drugs and corticosteroids were studied. Although some clinical improvement was seen in their musculoskeletal complaints, psoriasis was poorly controlled, requiring frequent inpatient admissions to hospital.

12 September 2021 in Helvetica Chimica Acta
Verified
Journal Article
Closed access
PDF file
PVPinelopi Voulgari
Pinelopi Voulgari
DADimitrios Alivertis
Dimitrios Alivertis
KSKONSTANTINOS SKOBRIDIS
KONSTANTINOS SKOBRIDIS

7 June 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
NGNafsika Gerolymatou
Nafsika Gerolymatou
NKNikolaos Koletsos
Nikolaos Koletsos
MKM. Karakosta
M. Karakosta
TMT. E. Memi
T. E. Memi
ADA. A. Drosos
A. A. Drosos
PVP. Voulgari
P. Voulgari
Background Systemic Sclerosis (SSc) is a connective tissue disease affecting multiple systems, including the respiratory and cardiovascular systems. Among the various disease complications, interstitial lung disease (ILD), pulmonary arterial hypertension (PAH) and -lately recognized- myocardial fibrosis (MF), are those mainly related to reduced life expectancy. Objectives We aimed to evaluate the prevalence of SSc complications and to investigate possible associations with patients’ clinical and serological characteristics. Methods Patients fulfilling the ACR/EULAR 2013 Scleroderma criteria, who were followed at our tertiary rheumatology centre between January 2018 and December 2022, were included in our cohort. Demographic, clinical, and serological characteristics, as well as imaging data (high-resolution chest CT, cardiac MRI) were used in our retrospective analysis. Results Ninety-one patients were included in our study, with 39.6% of them having diffuse cutaneous SSc. Most patients were female (81.3%), with a mean age at diagnosis 50.3 ±14.5 years and a mean disease duration 10.2 ±9.0 years. Leaving aside Raynaud’s phenomenon and sclerodactyly, gastrointestinal involvement (71.4%), ulcers (46.2%) and arthritis (45.1%) were among the most prevalent clinical manifestations. Mean baseline FEV1 and FVC values were normal (83.4%±16.8 and 84.4%±18.5 respectively, while mean baseline DLCO was pathological (62.6±18.9). All patients underwent a high-resolution CT early at diagnosis and upon rheumatologist’s/pulmonologist’s judgement afterwards. Eighty-one patients (89.0%) were diagnosed with interstitial lung disease (76.0% had NSIP pattern, 24.0% UIP pattern). Patients with NSIP had better scores in lung function tests than those with UIP pattern (Mean difference in FEV1, FVC and DLCO were 13,3%, 17,7%, and 12% respectively, p<0.05 for all comparisons). Positivity for anti-topoisomerase antibody (Scl-70) presented an OR=24.9 (p=0.001) for ILD, while ACA and anti-CENP-B were negatively associated (OR=0.114, p=0.003 and OR=0.164, p=0.024, respectively). Pulmonary hypertension based on echocardiogram findings was reported in 18/91 patients (19,8%), however PAH based on right heart catheterization (RHC) was confirmed in 11 of them (12,1% of total patients). Anti-Ro52 positivity was associated with PH (OR=4.45, p=0,005) and PH-ILD coexistence (OR=5.18, p=0,002), however no association was found for ILD presence in this cohort. There was also a trend for PAH-RHC, but it did not reach statistical significance. Cardiac MRI was performed in 24 patients, and non-ischemic myocardial fibrosis (compatible with SSc involvement) was identified in 18/24. The mean disease duration in MF group was longer (8.7 ±7.3 vs 3.3 ±4.3, p=0.040). Gastrointestinal involvement seems to confer an increased risk for this complication (OR=10.0, p=0.038). Conclusion The estimated ILD prevalence in our study is significantly higher than the one reported in the literature. As a referral centre, the patients reaching to our department probably have worse organ involvement than the average patient of primacy care setting. In addition, universal screening with a baseline HRCT and close monitoring lead to an earlier identification of this population. Anti-Ro52 has been recently reported as an independent risk factor for PAH. Our results could not verify this observation, probably due to the relatively small number of PAH patients in our study. Cardiac MRI availability and radiologist’s experience are essential for MF diagnosis. It is our belief that larger studies are necessary to evaluate this population. References [1]Khanna SA, Nance JW, Suliman SA. Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis. Curr Rheumatol Rep. 2022 May;24(5):166-173. [2]AYS Lee, KA Patterson et al (2021) Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients, Scand J Rheumatol, 50:6, 469-474. Acknowledgements: NIL. Disclosure of Interests None Declared.